Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
844.4 EUR | +1.48% |
|
-1.99% | +57.89% |
07-04 | ETF of the week: Investing in strong trends with the momentum theme | ![]() |
07-03 | Health Stocks Slip in Risk-On Trade -- Health Care Roundup | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 67.15 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+57.89% | 809B | - | ||
+39.52% | 624B | B | ||
-6.55% | 351B | C+ | ||
+7.92% | 289B | C+ | ||
+13.74% | 240B | B+ | ||
+13.83% | 220B | B- | ||
-0.49% | 219B | A+ | ||
+7.94% | 166B | C+ | ||
-2.57% | 157B | C+ | ||
+1.31% | 123B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LLY Stock
- LLY Stock
- Ratings Eli Lilly and Company